Search
PPI-2458
go.drugbank.com/drugs/DB05864InvestigationalThis class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases … In preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile.
Gestonorone
go.drugbank.com/drugs/DB13230ExperimentalGestonorone is often mistaken for gestonorone capproate which has a different chemical structure.
Categories: Sex Hormones and Modulators of the Genital SystemZelicapavir
go.drugbank.com/drugs/DB21662InvestigationalZelicapavir has a monoisotopic molecular weight of 549.17 Da. … Zelicapavir is under investigation in clinical trial NCT06601192 (A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults).
Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10598ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Phuket/3073/2013 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10599ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10601ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10602ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10773ApprovedInvestigationalWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10791ApprovedInvestigationalWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10794ApprovedInvestigationalWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen